俊裕地基(01757.HK)預計中期純利不少於約200萬港元
格隆匯11月24日丨俊裕地基(01757.HK)公佈,集團截至2021年9月30日止六個月預料將錄得純利不少於約200萬港元,而截至2020年9月30日止六個月則錄得淨虧損約670萬港元。
有關期間的預計盈利與截至2020年9月30日止六個月的淨虧損相比,乃主要由於:(i)收益增加約1.53億港元,乃由於有關期間位於啟德及深水埗的兩個項目取得巨大進展所致。(ii)毛利率由截至2020年9月30日止六個月的約2.4%提升至於有關期間的4.3%,乃由於在更大運營規模下使用機器的效率提高,並且在更大的收益水平下分擔更多固定成本。隨着收益增加,於有關期間的毛利增加約870萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.